27 terminated. 27 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 27 | Terminated 27 |
Follow Coronavirus Infections: new trials by email Literature Review of Coronavirus Infections trials Research Report on Coronavirus Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of NVX-CoV2705 NVX-CoV2705, Placebo - COVID-19, Sars-CoV-2 Infection | Phase 4 | Terminated | Novavax | 6500 | 2025-11-20 | 2026-10-23 |
| Addressing Cognitive Fog in Long-COVID-19 Patients Digital cognitive behavioral intervention-RxWell, Amphetamine-Dextroamphetamine - Cognitive Impairment, Long COVID | Phase 4 | Terminated | Eva Szigethy | 7 | 2023-04-04 | 2024-07-22 |
| Endothelial Protection in Convalescent COVID-19 Patients Sulodexide - Endothelial Dysfunction, Inflammation | Phase 4 | Terminated | Pirogov Russian National Research Medical University | 2 | 2022-04-01 | 2025-06-13 |
| A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults AZD1222 - COVID-19, SARS-CoV-2 | Phase 4 | Terminated | AstraZeneca | 34 | 2022-01-31 | 2025-01-27 |
| COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2 Spikevax, Comirnaty, Spikevax bivalent Original/Omicron BA.1 - Cancer | Phase 4 | Terminated | Jules Bordet Institute | 152 | 2021-12-01 | 2024-01-17 |
| Echinaforce COVID-19 Shedding Study Echinaforce Forte tablets, Echinaforce Chewable tablets, Echinaforce tincture - COVID-19 Respiratory Infection, SARS-CoV2 Infection | Phase 4 | Terminated | A. Vogel AG | 40 | 2021-11-15 | 2024-08-06 |
| Cohort Assessing the Immunogenicity and the Safety of the COVID-19 Vaccine Janssen in Healthy Volunteers Based on 2 Age Groups: 65 Years or Older - 55 to 65 Years. Covicompare-Janssen COVID-19 Vaccine Janssen (Ad26.COV2-S) - Healthy Volunteers | Phase 4 | Terminated | Centre Hospitalier Universitaire de Saint Etienne | 27 | 2021-09-20 | 2025-02-10 |
| A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate - Relapsing Multiple Sclerosis (RMS) | Phase 4 | Terminated | Novartis Pharmaceuticals | 24 | 2021-06-10 | 2025-05-16 |
| UPMC OPTIMISE-C19 Trial, a COVID-19 Study Lilly Bamlanivimab, Regeneron Casirivimab + Imdevimab, Lilly Bamlanivimab + Etesevimab - Covid19 | Phase 4 | Terminated | Erin McCreary | 4571 | 2021-03-10 | 2023-06-15 |
| Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19 Apixaban 2.5 MG, Placebo - Covid19, Thrombosis | Phase 4 | Terminated | Brazilian Clinical Research Institute | 411 | 2021-03-04 | 2022-08-25 |
| COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study Dexamethasone - Covid19, Corona Virus Infection | Phase 4 | Terminated | General Practitioners Research Institute | 17 | 2021-02-16 | 2021-05-11 |
| Treatment of Nosocomial COVID-19 Anti-SARS-CoV-2 mAb - Covid19, Nosocomial Infection | Phase 4 | Terminated | University of Calgary | 46 | 2021-02-12 | 2023-04-19 |
| Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients Dexamethasone, Methylprednisolone - Corona Virus Infection | Phase 4 | Terminated | Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León | 128 | 2021-02-01 | 2025-01-06 |
| At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19 bamlanivimab - Covid19 | Phase 4 | Terminated | Daniel Griffin | 139 | 2021-01-04 | 2022-03-18 |
| Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) Enoxaparin sodium, Unfractionated heparin, Fondapariniux - COVID-19 | Phase 4 | Terminated | Weill Medical College of Cornell University | 14 | 2020-10-13 | 2023-09-21 |
| Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Sodium bicarbonate, Standard of Care - COVID, Coronavirus | Phase 4 | Terminated | West Virginia University | 3 | 2020-10-05 | 2023-12-22 |
| COVID-19 Antithrombotic Rivaroxaban Evaluation Rivaroxaban 10 mg - COVID-19 | Phase 4 | Terminated | Hospital Alemão Oswaldo Cruz | 660 | 2020-09-29 | 2023-01-25 |
| A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults Icosapent ethyl - Covid19, Atherosclerosis | Phase 4 | Terminated | Kaiser Permanente | 39600 | 2020-08-07 | 2023-07-18 |
| Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury Heparin, 0.9% Sodium-chloride - Covid-19, ARDS, Human | Phase 4 | Terminated | Frederick Health | 13 | 2020-06-01 | 2024-04-03 |
| Hyperbaric Oxygen Therapy in Non-ventilated COVID-19 Patients Hyperbaric Oxygen Therapy - COVID, Coronavirus | Phase 4 | Terminated | Maimonides Medical Center | 1 | 2020-06-01 | 2021-06-29 |
Showing 20 of 27. Sign in to see all of them.
COVID-19 (23) · Respiratory Distress Syndrome (3) · Thrombosis (2) · Acute Kidney Injury (1) · Acute Lung Injury (1) · Asymptomatic Diseases (1) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Cognitive Dysfunction (1) · Cross Infection (1) · Inflammation (1) · Multiple Organ Failure (1) · Multiple Sclerosis (1) · Neoplasms (1)
Coronaviridae Infections (27) · Infections (27) · Nidovirales Infections (27) · RNA Virus Infections (27) · Virus Diseases (27) · Lung Diseases (24) · Pneumonia (24) · Pneumonia, Viral (24) · Respiratory Tract Diseases (24) · Respiratory Tract Infections (23) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Disease Attributes (3) · Respiration Disorders (3)
Chloroquine (3) · Dexamethasone (3) · Heparin (2) · Hydroxychloroquine (2) · bamlanivimab (2) · sotrovimab (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Ad26COVS1 (1) · Adderall (1) · BNT162 Vaccine (1) · CVnCoV COVID-19 vaccine (1) · ChAdOx1 nCoV-19 (1) · Enoxaparin (1) · Fondaparinux (1) · Glatiramer Acetate (1)
Government of Punjab, Specialized Healthcare and Medical Education Department (2) · A. Vogel AG (1) · AstraZeneca (1) · Brazilian Clinical Research Institute (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Daniel Griffin (1) · Erin McCreary (1) · Eva Szigethy (1) · Frederick Health (1) · Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León (1) · Fundación para la Investigación del Hospital Clínico de Valencia (1) · General Practitioners Research Institute (1) · Hospital Alemão Oswaldo Cruz (1) · Hospital Universitario de Gran Canaria Doctor Negrín (1) · Hugo Mendieta Zeron (1)
United States (10) · Netherlands (3) · Spain (3) · Brazil (2) · Pakistan (2) · Belgium (1) · Bulgaria (1) · Canada (1) · France (1) · Mexico (1) · Russia (1) · Thailand (1) · Ukraine (1)
Alain Tremblay (1) · Ammar Sarwar, MD (1) · Ankit Sakhuja, MD (1) · Dan Griffin, MD, PHD (1) · David T Huang, MD, MPH (1) · Erin McCreary, PharmD (1) · Eva Szigethy, MD, PhD (1) · Janwillem Kocks, Prof (1) · Kirill Lobastov, PhD (1) · Luis Corral Gudino (1) · Maria T DeSancho, MD, MSc (1)
PMID 34473343, PMID 35244208, PMID 37591523, PMID 27449641, PMID 32043986, PMID 32512291, PMID 32513231, PMID 32799933, PMID 33502773, PMID 34034784, PMID 35697146, PMID 35713300, PMID 35834252, PMID 37018790, PMID 37223666